Viridian reports positive Phase 3 results for chronic thyroid eye disease drug

May 5, 2026 7:00 AM

Viridian Therapeutics Inc. (NASDAQ: VRDN) announced that its Phase 3 REVEAL-2 clinical trial of elegrobart met its primary endpoint for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found